| LMT |
Report |
Revenue |
IN-LINE |
pred ~$19.42B vs. cons $19.28B |
MEDIUM |
| LMT |
Report |
Diluted EPS |
BEAT |
pred ~$7.32 vs. cons $7.15 |
MEDIUM |
| LMT |
Report |
Free cash flow |
MISS |
pred ~$0.35B vs. cons $0.80B |
LOW |
| LMT |
Guide |
FY2026 sales guidance |
UNCHANGED |
guide ~$78.75B vs. cons $78.80B (FY2026) |
HIGH |
| LMT |
Guide |
FY2026 diluted EPS guidance |
LOWER |
guide ~$29.80 vs. cons $30.00 (FY2026) |
MEDIUM |
| LMT |
Guide |
FY2026 free-cash-flow guidance |
UNCHANGED |
guide ~$6.65B vs. cons $6.65B (FY2026) |
MEDIUM |
| LMT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| LMT |
Return |
5-day cumulative residual |
-1.5% (STABILIZE) |
A ~$0.17 EPS beat versus $7.15 and ~$0.14B revenue beat versus $19.28B should be outweighed initially by a ~$0.45B quarterly FCF shortfall versus $0.80B and an unchanged ~$6.65B FY2026 FCF guide versus $6.65B consensus. With FY2026 sales guide near $78.75B versus $78.80B consensus and EPS guide near $29.80 versus $30.00, out-period estimate cuts should be limited; the initial cash-conversion disappointment is therefore more likely to stabilize than drive a continuing revision-led selloff. |
MEDIUM |